Lixte Historical Balance Sheet

About Lixte Balance Sheet Analysis

Profit & Loss Statement Details

Cash Flow Statement Details

Financial Indicators Details

Valuation Indicators Details

Lixte Biotechnology Balance Sheet Chart

At this time, Lixte Biotechnology's Total Stockholder Equity is comparatively stable compared to the past year. Cash is likely to gain to about 4.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.

Total Assets

Total assets refers to the total amount of Lixte Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lixte Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lixte Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lixte Biotechnology Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lixte Biotechnology balance sheet. This account contains Lixte Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lixte Biotechnology Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Accounts Payable

An accounting item on the balance sheet that represents Lixte Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lixte Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Lixte Biotechnology balance sheet Correlations

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology balance sheet Accounts

Additional Tools for Lixte Stock Analysis